{"id":391230,"date":"2015-11-30T00:00:00","date_gmt":"2015-11-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1515-biopharma-prostate-cancer-u-s-physician-and-payer-perspectives-on-novel-treatment-options-for-prostate\/"},"modified":"2026-03-31T09:02:46","modified_gmt":"2026-03-31T09:02:46","slug":"pforus1515-biopharma-prostate-cancer-u-s-physician-and-payer-perspectives-on-novel-treatment-options-for-prostate","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1515-biopharma-prostate-cancer-u-s-physician-and-payer-perspectives-on-novel-treatment-options-for-prostate\/","title":{"rendered":"Prostate Cancer (U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer) | Physician &#038; Payer Forum | US | 2015"},"content":{"rendered":"<p>The <em>U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer <\/em>report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture their views on anticipated prescribing, reimbursement, and market access barriers in relation to current and emerging agents in prostate cancer. Five premium-priced therapies\u2014Zytiga (Johnson &#038; Johnson), Xtandi (Medivation), Provenge (Valeant), Xofigo (Bayer), and Jevtana (Sanofi)\u2014are approved in the United States for prostate cancer, driving the metastatic castrate-resistant prostate cancer (mCRPC) market to become increasingly crowded and competitive. As novel therapies aim to enter this market, sequencing of treatments and gaining optimal reimbursement will be of increasing importance.<\/p>\n","protected":false},"template":"","class_list":["post-391230","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-therapy-areas-prostate-cancer","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391230\/revisions"}],"predecessor-version":[{"id":576914,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391230\/revisions\/576914"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}